Zenas BioPharma sets price range for $200 million initial public offering

Date:

September 6, 2024

Zenas BioPharma Inc., a Waltham, Mass.-based developer of immunology-based therapies, on Friday said it plans to offer 11.76 million shares of common stock at an estimated price range of $16 to $18 in its upcoming initial public offering.

Source link

Google faces provisional antitrust charges in UK for ‘self-preferencing’ its ad exchange

You Won't Believe How Much High-Income Earners Save for Retirement

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Zenas BioPharma sets price range for $200 million initial public offering

Recent posts

Harris sees ‘next generation of breakthroughs’ built by U.S. workers. AI, crypto could benefit.

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Wall Street is going all-in on election betting markets. What you need to know.

What’s next for bond markets after a week of wild volatility

Record gold prices are in a ‘different world’ than silver and copper. Here’s why.

Harris now leads Trump in swing-state polls, according to one polling average

Oil prices lifted by report Iran may be planning another major strike on Israel

U.S. household energy bills won’t shock consumers this winter

This popular ‘Trump trade’ may have run its course — at least for now, strategist says

Mohawk Industries’ stock rallies as flooring-products maker draws upgrade on boosted profit view

WK Kellogg is upbeat about going it alone as CEO says ‘don’t sleep on our core brands’

Expectations had dimmed for the IPO of Bill Ackman’s new fund. Now, the offering is being pulled.

UBS to put Credit Suisse Real Estate Fund International into liquidation

A Trump White House could see M&A uptick in these sectors

Spirit Airlines lowers revenue estimates as it faces more competition, capacity challenges

Related articles

Trump’s choice of Dr. Oz to oversee Medicare and Medicaid could be ‘devastating’ for millions of Americans

Buy gold after its pullbacks — because it may hit $3,000 in 2025

Bitcoin sits near record high. More good news for investors: It’s now less volatile.

RFK Jr. may start a food and drug ‘culture war.’ Investors are running for cover.

Here’s what bond and gold traders are signaling about Russia’s nuclear shift

Stock market ‘finally paying more attention to tariffs’ as a potential headwind

Investors are bracing for higher-for-even-longer interest rates

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Company

Follow us